DEA Rescheduling Moves Forward: What Cannabis Users Need to Know in 2026

The Long Road to Rescheduling

After decades of advocacy, court battles, and political gridlock, the Drug Enforcement Administration's proposal to move cannabis from Schedule I to Schedule III of the Controlled Substances Act is finally making tangible progress in 2026. The Department of Justice formally published its notice of proposed rulemaking in late 2025, and the public comment period — which drew over 40,000 responses — closed in January.

This is the most significant shift in federal cannabis policy since the Controlled Substances Act was passed in 1970. For millions of consumers, patients, and businesses, the implications are enormous — and the timeline is finally starting to come into focus.

What Schedule III Actually Means

Under the current Schedule I designation, cannabis is classified alongside heroin as having "no accepted medical use" and "high abuse potential" — a classification that has been widely criticized by medical researchers, patient advocates, and now, the Department of Health and Human Services itself, which recommended rescheduling in 2023.

Moving to Schedule III would place cannabis in the same category as ketamine and some anabolic steroids. Practically speaking, this means:

Banking access opens up. One of the biggest pain points for cannabis businesses — the inability to access traditional banking — stems from federal law. Schedule III status would remove the primary barrier for banks and credit unions to service cannabis companies without fear of federal prosecution.

Research restrictions ease. Cannabis researchers have long been hampered by Schedule I restrictions that limit which institutions can study the plant and how. Rescheduling would dramatically expand research capacity, which advocates say could accelerate medical discoveries around strains like Harlequin and ACDC that are rich in therapeutic cannabinoids.

Tax burden on dispensaries drops. The notorious 280E tax provision of the IRS code, which prevents cannabis businesses from deducting normal business expenses, applies specifically to Schedule I and II substances. Schedule III would remove cannabis from 280E, potentially saving the industry billions annually.

Which States Are Watching Closely

The rescheduling conversation has reinvigorated legalization efforts in several holdout states. Florida, South Carolina, and Kentucky all have active adult-use bills moving through their legislatures in 2026, with advocates citing the federal shift as political cover for traditionally conservative legislators to support reform.

In states where cannabis is already legal, operators are cautiously optimistic. "This changes the financial math completely," said one Colorado dispensary owner who requested anonymity. "We've been paying an effective tax rate of 70% or higher because of 280E. Fixing that alone could save our store."

The Opposition Isn't Going Quietly

Not everyone is celebrating. Several law enforcement associations and anti-drug organizations have filed formal objections to the rulemaking, and at least two lawsuits challenging the DEA's authority to reschedule without an act of Congress are winding through federal courts.

Legal experts say the challenges have merit but are unlikely to succeed, pointing to the broad administrative authority granted to the DEA under the Controlled Substances Act. "The DEA has rescheduled substances before without congressional action," noted one federal drug policy attorney. "The legal framework supports this."

What This Means For You

If you're a consumer in a legal state, the day-to-day experience of buying cannabis won't change immediately. But the downstream effects — more dispensaries staying open as businesses become financially viable, more research validating therapeutic uses, and a cultural shift in how the federal government talks about cannabis — will ripple outward over the next few years.

For those in illegal states, rescheduling isn't legalization. But it is the clearest signal yet that the federal government is no longer treating cannabis as a public enemy. The question is no longer if federal cannabis policy changes — it's how fast.

Browse our guide to cannabinoid profiles to understand the science behind why rescheduling matters for medical research, or explore strains like Blue Dream that have driven consumer adoption in legal markets. And check out ILGM — one of the most trusted seed banks serving US customers — to see how the legal market is evolving.